Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mixed oral plaque bacteria and volatile sulfur compound (VSC) precursors represent a complex biological target system primarily associated with oral malodor and periodontal health. The target consists of anaerobic Gram-negative bacteria, such as Porphyromonas gingivalis, Treponema denticola, and Prevotella intermedia, which reside within the dental plaque biofilm (Source: PubMed PMID: 15752094). These microorganisms utilize proteolytic enzymes to metabolize sulfur-containing amino acids—specifically cysteine and methionine—found in saliva and food debris (Source: PubMed PMID: 24564061). This metabolic process results in the production of VSCs, including hydrogen sulfide and methyl mercaptan, which are the principal components of halitosis. Therapeutic strategies targeting this system involve the use of antiseptic agents to reduce bacterial density and metal ions, like zinc, which inhibit the enzymatic breakdown of precursors or chemically neutralize the resulting gases (Source: PubMed PMID: 12787205). Effective management of this target is essential for both cosmetic breath control and the prevention of inflammatory oral diseases.
Antimicrobial agents reduce the total load of anaerobic bacteria; metal ions (e.g., Zinc) bind to thiol groups of precursors to prevent conversion or directly neutralize VSCs; oxidizing agents convert VSCs into non-volatile forms.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mixed oral plaque bacteria and volatile sulfur compound precursors.